NATCO settles on Lenalidomide for Canada

Natco Pharma (Canada) Inc., Canada, a subsidiary of Natco Pharma Limited has entered into a settlement agreement with Celgene (now part of Bristol-Myers Squibb) for the product Lenalidomide Capsules in Canada. The terms of the agreement are confidential as per the agreement.

Shares of NATCO PHARMA LTD. was last trading in BSE at Rs.676.5 as compared to the previous close of Rs. 684.55. The total number of shares traded during the day was 8013 in over 607 trades.

The stock hit an intraday high of Rs. 689.65 and intraday low of 672. The net turnover during the day was Rs. 5429376.

Source : Equity Bulls

Keywords